Therapeutics for Women's Health: Technologies and Global Markets
The global market for women’s health therapeutics was worth nearly $18.3 billion in 2012. The market is expected to increase from nearly $19 billion in 2013 to nearly $22.5 billion by 2018, a compound annual growth rate (CAGR) of 3.5% for the five-year period, 2013 to 2018.
- An overview of the global therapeutics for women's health market.
- Analyses of global market trends, with data from 2012 and 2013, and projections of CAGRs through 2018.
- Information on women's health disorder types including infertility, endometriosis, postmenopausal osteoporosis, menopause, and polycystic ovary syndrome (PCOS).
- Detailed analysis of annual costs as well discussion on branded vs. generics.
- Specifics on market factors such as drivers, restraints, competition, and market shares.
- Information on marketed as well as pipeline drugs and therapies.
This report is an analytical business tool whose primary purpose is to describe the thorough evaluation of the global market for women's health therapeutics. The format of the study is organized around the following topics:
- Detailed study around women's diseases such as endometriosis, postmenopausal osteoporosis, menopause and polycystic ovary syndrome (PCOS).
- Disease incidence and prevalence.
- Regulatory structure.
- Market characterization, unmet need, market size and segmentation.
- Market drivers and restraints.
- Detailed market projections through 2018.
- Competition and market shares.
- Pricing and reimbursement.
- Marketed and pipeline (R&D) products along with description, regulatory status and clinical trials.
- Observations and conclusions regarding the future of women's health therapeutics market.
- Profiles of market participants and associations.
Dr. Ritu Thakur is an independent consultant based in New Delhi, India with 10+ years of experience in consulting, business/market research, business & report writing, analytics, content development & management and translation. She has prior work experience with Panasonic (Healthcare Division), GlobalData (U.K.-based market research firm) and several other development stage/early stage companies including Biovo, Diabesity, Medibrane, ScaleThings, EndoGI, Ramot Biomedical Eng and NeverWet. In her previous assignments, she has delivered hundreds of small to large scale custom projects on pharmaceutical, medical and biotechnology subjects. She has developed reports for BCC Research for more than four years and has worked as an author for healthcare and other related industries such as pharmaceuticals, biotechnology and medical devices.
- Bariatric Surgery: Global Markets for Services and Devices (HLC153B).
- Wearable Medical Devices: Technologies and Global Markets (HLC192A).
- Global Markets for Emerging Medical Device Technologies (HLC191A).
- Needle-Free Devices: Technologies and Global Markets (HLC178A).
- Medication Automation: Systems, Technologies and Global Markets (PHM182A).
- Smart Pills: Applications and Global Markets (PHM181A).
- The U.S. market for therapeutics and diagnostics for women’s disorders was worth $29.9 billion in 2008. This should increase to $50.0 billion in 2013, for a compound annual growth rate (CAGR) of 10.9%.
- The rheumatoid arthritis and osteoporosis segment has the largest share of the market, generating $10.6 billion in 2008. This is expected to grow at a CAGR of 11.5% to reach $18.2 billion in 2013.
- Reproductive related therapies and diagnostics currently have the second largest market share, worth $5.9 billion in 2008. This should reach $7.5 billion in 2013, for a CAGR of 5.0%.
The total U.S. market for new therapeutics and diagnostics for women’s disorders was estimated at more than $25 billion in 2004 and is expected to reach nearly $41 billion in 2009, rising at an AAGR (average annual growth rate) of 10.3%.
Treatments for cancers specific to women will rise the fastest, at an AAGR of 12.6% and will lead revenues in 2009.
Reproductive-related therapies and diagnostics currently represent the largest market segment, but, rising at an AGR of 8.4%, will lag slightly by 2009.
Treatments for gynecological diseases and infections and for rheumatoid arthritis and osteoporosis also represent large market segments.
The total current U.S. market for new therapeutics and diagnostics for women's disorders in 1999 reached $16.9 billion at the manufacturers' level. The growing numbers of women combined with the growing trend to take an active role in healthcare has driven growth in this market. By 2005, it is anticipated that revenues will likely reach $31.9 billion, growing at an average annual rate of 8.7%.
The reproductive-related therapeutics and diagnostics holds the largest market revenues position representing 31.9% and accounting for $5.4 billion of the total in 1999. Large numbers of women in the baby boomer age group, coupled with large numbers of the mini-boomers (daughters of the baby boomer generation), contributed to the reproductive-related therapeutics and diagnostics' dominate role in 1999. It is anticipated that the reproductive-related therapeutics and diagnostics will remain the largest market share throughout the forecast period as it crosses $10 billion by 2005.